Author: Gary Bridgman

SJELIOT clinical trial explores a new approach for recurring and unresponsive medulloblastoma tumors

A new St. Jude Children’s Research Hospital clinical trial, SJELIOT, is evaluating an adult cancer drug that shows potential for improved treatment of high-risk pediatric brain tumors. This phase I investigation is evaluating the combination of a kinase inhibitor (prexasertib) with established anti-cancer agents in children and adolescents who have recurrent or refractory (unresponsive) medulloblastoma, the most common malignant brain tumor in childhood. Leading SJELIOT is neuro-oncologist Giles Robinson, MD, who is also running the SJDAWN clinical trial. “We are very excited to launch this clinical trial,” Robinson said, “since it translates years of very promising laboratory work by...

Read More

Stay Current on St. Jude News

Subscribe for regular updates on St. Jude leadership, research, and clinical care

Recent Tweets

Recent Videos